# Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

> **NCT05503550** · — · NO_LONGER_AVAILABLE · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Talquetamab

## Key facts

- **NCT ID:** NCT05503550
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05503550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05503550, "Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05503550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*